stockrowAdaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.
- Revenue
- −10.7%
- EPS
- −66.7%
- Free cash flow
- +201.9%
Quarter to September 2026, against a year earlier
Follow ADPT
Alert me
Adaptive Biotechnologies Corporation (ADPT) Net income
Adaptive Biotechnologies Corporation's net income for fiscal 2025 was −$59.5M, compared with −$159.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$70.7M. Over the past ten years it has ranged from −$225.3M (fiscal 2023) to −$42.8M (fiscal 2017); the current reading is higher than 78% of that period. Adaptive Biotechnologies Corporation ranks 40th of 49 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$59.5M | — |
| FY2024 | −$159.6M | — |
| FY2023 | −$225.3M | — |
| FY2022 | −$200.4M | — |
| FY2021 | −$207.3M | — |
| FY2020 | −$146.2M | — |
| FY2019 | −$68.6M | — |
| FY2018 | −$46.4M | — |
| FY2017 | −$42.8M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $2.8M | — |
| Jun 2026 | −$39.9M | — |
| Mar 2026 | −$20.0M | — |
| Dec 2025 | −$13.6M | — |
| 31 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| SHC Sotera Health Company compare | $173.5M |
| CDNA CareDx, Inc. compare | $128.6M |
| VCYT Veracyte, Inc. compare | $126.8M |
| BLLN BillionToOne, Inc. compare | $49.4M |
| RDNT RadNet, Inc. compare | $19.3M |
| NEO NeoGenomics, Inc. compare | −$32.3M |
| ADPT Adaptive Biotechnologies Corporation | −$70.7M |
| WGS GeneDx Holdings Corp. compare | −$106.4M |
| GRAL GRAIL, Inc. compare | −$406.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ADPT
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement